Scrip’s Latest Taster Content

In this week's episode: Merck’s case for Terns and more deals; Boehringer’s warning on innovation-unfriendly Europe; how Kelun-Merck pact changed China deal-making; neuroscience R&D regains ground; and new US LDL-C guidelines and drug costs.

Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.

In this week's episode: many blockbusters to fade this year: semaglutide’s India reckoning; multinationals look beyond simple China licensing; Almirall eyes China dermatology assets; EU urged to restore biopharma competitiveness.

Inside the operational, technical, and strategic decisions behind scaling a complex sterile vaccine program in under two years

Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.

In this week's episode: Roche faces giredestrant Phase III setback; founders exit BioNTech; Ipsen to withdraw Tazverik; tough times for Bayer; and another boost for UCB’s Bimzelx.

In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.

A new wave of commercial-stage biopharmas are interested in launching drugs in Europe but weighing risks related to US drug pricing policies